From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Pediatrics and Adolescent Medicine>
  4. Summary and Comment

Reducing the Rate of Prematurity

Progesterone shows promise.

The rate of prematurity (birth before 37 weeks of gestation) continues to increase in the U.S., in part because of assisted fertilization. Preventing prematurity, particularly birth before 34 weeks, has been the subject of intensive research.

In a multisite, randomized, double-blind clinical trial, investigators used transvaginal ultrasound to screen 24,620 women at 20 to 25 weeks of gestation; 413 women with a cervical length of less than 15 mm received vaginal progesterone (200 mg at night) or placebo from 24 to 34 weeks of gestation. Women who received progesterone were significantly less likely than women in the placebo group to deliver an infant before 34 weeks of gestation (19.2% vs. 34.4%).

In another multisite, randomized, double-blind clinical trial, 655 women with twin gestations received either weekly intramuscular injections of progesterone (250 mg) or placebo, beginning at 16 to 20 weeks of gestation and ending at 35 weeks. No significant differences between groups were noted in the incidence of delivery or fetal death before 35 weeks (41.5% and 37.3% in the progesterone and placebo groups, respectively) or the rate of prespecified serious adverse fetal or neonatal outcomes (20.7% vs. 18.4%, respectively).

Comment: The results of the first study indicate that identifying and preventing premature delivery in high-risk women is possible, although widespread screening would be necessary to substantially affect rates of prematurity. The results of the second study suggest that the etiology of prematurity in twin gestations is likely different from that of singleton gestations.

Howard Bauchner, MD

Published in Journal Watch Pediatrics and Adolescent Medicine August 1, 2007

Citation(s):

Fonseca EB et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007 Aug 2; 357:462-9.

Rouse DJ et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007 Aug 2; 357:454-61.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Other Perspectives

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.